Plymouth-based Fraunhofer USA Center for Biotechnology was awarded a
$2.6 million research grant from the United States Department of Defense's
Defense Advanced Research Projects Agency (DARPA) to study accelerated
manufacturing of pharmaceuticals.
Excerpt:
The total value of the effort, if all phases of the development program are completed, could be $8.5 million.
Under Phase I of the DARPA contract, Fraunhofer USA CMB will validate its plant-based technology platform for the rapid, cost-effective production of vaccines and monoclonal antibodies. The Fraunhofer USA CMB platform can significantly reduce the time required from the identification of infectious agents to the manufacture of millions of doses of medical countermeasures.
Read the entire article here.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.